Effects of GLP-1 on Chronic Heart Failure

• Status: Unknown status
• Trial end date: 2018-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators planned to evaluate the effects of liraglutide on left ventricular function in chronic heart failure patients with type 2 diabetes.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shi Yang
• Treatments: Glucagon-Like Peptide 1; Liraglutide

Criteria

Inclusion Criteria:

• Chronic heart failure patients with type 2 diabetes (NYHA-class I, II or III) were eligible for the study

Exclusion Criteria:

• CHF (NYHA class IV)

• Type 1 diabetes

• Hospitalisation due to incompensated heart disease within 30 days prior to randomisation

• Myocardial infarction within the past 3 months before screening

• Coronary revascularisation within the past 3 months before screening

• Atrial fibrillation with ventricular frequency >100/min in rest

• ECG suggestive of malignant ventricular arrhythmia

• Prolonged QT-interval (>500 ms)

• Valvular heart disease

• Current myocardial or pericardial infection

• Obstructive hypertrophic cardiomyopathy

• Cancer unless in complete remission for ≥5 years

• Acute pancreatitis

• Compromised kidney function (eGFR <30 mL/min), dialysis or kidney transplantation

• History of thyroidea adenoma or carcinoma